NCT07936279 Geriatric Hip Fracture mFI-5 for Postoperative ICU Need and 30 Day Mortality
| NCT ID | NCT07936279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital |
| Condition | Hip |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-05-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-07-01 with a primary completion date of 2027-05-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, observational, single-center study aims to evaluate the predictive value of the Modified Frailty Index-5 (mFI-5) score on postoperative intensive care unit (ICU) admission requirements and 30-day mortality in geriatric patients undergoing hip fracture surgery. Patients aged 65 and older presenting with a hip fracture will be evaluated preoperatively using the mFI-5 scoring system (assessing diabetes, hypertension, COPD, congestive heart failure, and functional dependence). Intraoperative hemodynamic data, anesthesia type, and transfusion requirements will be documented. Postoperative ICU admission, total hospital stay, and 30-day survival status will be recorded to assess the prognostic capability of preoperative frailty levels.
Eligibility Criteria
Inclusion Criteria: Patients aged 65 years and older. Diagnosed with a hip fracture (including femoral neck, intertrochanteric, or subtrochanteric fractures). Scheduled to undergo surgical treatment for the hip fracture. Anesthesia management planned under general or regional (spinal/epidural) anesthesia. American Society of Anesthesiologists (ASA) physical status classification I, II, III, or IV. Written informed consent provided voluntarily by the patient or their legally authorized representative prior to surgery. Exclusion Criteria: Patients under 65 years of age. Presence of high-energy injuries, major head trauma, or multiple trauma (polytrauma). Patients who are intubated or require mechanical ventilation in the preoperative period. Pathological fractures secondary to primary bone malignancies or bone metastases (if applicable per protocol). Refusal to undergo surgery or failure/refusal to provide written informed consent. Patients with missing 30-day postoperative follow-up data or incomplete medical records.
Contact & Investigator
Özge K Cihangir Özek, MD
PRINCIPAL INVESTIGATOR
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Frequently Asked Questions
Who can join the NCT07936279 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 70 Years, studying Hip. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07936279 currently recruiting?
Yes, NCT07936279 is actively recruiting participants. Contact the research team at ozgecigangirozek@hotmail.com for enrollment information.
Where is the NCT07936279 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07936279 clinical trial?
NCT07936279 is sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The principal investigator is Özge K Cihangir Özek, MD at Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The trial plans to enroll 200 participants.